Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Serum Bio Technology Co has a current ratio of 26.40. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Shanghai Serum Bio Technology Co's Current Ratio or its related term are showing as below:
SHSE:688163'
s Current Ratio Range Over the Past 10 Years
Min: 1.39 Med: 34.01 Max: 77.52
Current: 26.4
During the past 13 years, Shanghai Serum Bio Technology Co's highest Current Ratio was 77.52. The lowest was 1.39. And the median was 34.01.
SHSE:688163's Current Ratio is ranked better than 95.17% of 1409
companies
in the Biotechnology industry
Industry Median: 3.88
vs SHSE:688163: 26.40
Shanghai Serum Bio Technology Co (SHSE:688163) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Shanghai Serum Bio Technology Co Current Ratio Related Terms
Shanghai Serum Bio Technology Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Serum Bio Technology Co Current Ratio Chart
SHSE:688163 vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, Shanghai Serum Bio Technology Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Serum Bio Technology Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Serum Bio Technology Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Shanghai Serum Bio Technology Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Serum Bio Technology Co (SHSE:688163) has a Current Ratio of 26.40 as of Mar. 2026. This is 22% below median its historical median of 34.01. Over the past decade, Shanghai Serum Bio Technology Co's Current Ratio has ranged from 1.39 to 77.52. According to the industry distribution chart, Shanghai Serum Bio Technology Co ranks #68 out of 1409 companies in the Biotechnology industry, placing it in the top 4.8%.
Is Shanghai Serum Bio Technology Co's Current Ratio too high?
Shanghai Serum Bio Technology Co's current Current Ratio of 26.40 is 22% below median its 10-year median of 34.01. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 77.52. The Biotechnology industry median Current Ratio is 3.88. Shanghai Serum Bio Technology Co's value of 26.40 is 580.4% above this industry median. Based on the distribution chart, Shanghai Serum Bio Technology Co ranks #68 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Serum Bio Technology Co has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Serum Bio Technology Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Serum Bio Technology Co ranks #68 out of 1409 companies for Current Ratio. This places Shanghai Serum Bio Technology Co in the top 5% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. Shanghai Serum Bio Technology Co's value of 26.40 is 580.4% above this benchmark. Historically, Shanghai Serum Bio Technology Co's own Current Ratio has ranged from 1.39 to 77.52 over the past decade. While the company's 10-year median is 34.01 vs. the industry median of 3.88, Shanghai Serum Bio Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Serum Bio Technology Co's current Current Ratio of 26.40 is 580.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Serum Bio Technology Co's current Current Ratio is 26.40, which is 22% below median its own 10-year median of 34.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Serum Bio Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Serum Bio Technology Co (SHSE:688163) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥24.93, compared to a current price of ¥28.42 — trading 14% above its estimated fair value. The current Current Ratio is 26.40, which is 22% below median its 10-year median of 34.01 and 580.4% above the Biotechnology industry median of 3.88. Shanghai Serum Bio Technology Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Shanghai Serum Bio Technology Co (SHSE:688163), the current Current Ratio is 26.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Serum Bio Technology Co (SHSE:688163) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Serum Bio Technology Co stock appears to be overvalued.
The current stock price of ¥28.42 is trading 14% above its estimated GF Value™ of ¥24.93.
GuruFocus considers Shanghai Serum Bio Technology Co to be Modestly Overvalued.
Key valuation signals for SHSE:688163:
Current Ratio: 26.40 (22% below median its 10-year median of 34.01)
GF Value™: ¥24.93 vs. price of ¥28.42 (14% above fair value)
Industry Position: 580.4% above the Biotechnology median (#68 of 1409)
No single metric tells the full story. See the SHSE:688163 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Serum Bio Technology Co Business Description
Shanghai Serum Bio Technology Co Ltd is engaged in the research, development, production and sales of preventive and therapeutic drugs in the field of biotoxins and biosafety.
71GF Score
Get the complete analysis for SHSE:688163
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688163 has been successfully added to your 
